Prne
June 30th, 2009
GENEVA, Switzerland -
- Global Fertility Academy Delivers Valuable Educational Tools Aiming at Increasing Expertise and Maximizing the Success Rate of Treatment
- Web-based e-Learning Modules Complemented by Individualized Practical Training Sessions at Leading Fertility Centers Worldwide
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the launch of the Global Fertility Academy, the first global professional educational program in fertility run by worldwide leading experts in this area.(1) Specifically developed for physicians active in treating infertility, such as reproductive endocrinologists, obstetricians/gynecologists and embryologists, the Global Fertility Academy aims at improving their knowledge of clinical standards in fertility and maximizing the success rates of treatment by providing valuable educational tools and sharing best practices. The Global Fertility Academy is available to healthcare professionals outside of the United States and Great Britain.
The educational program proposed by the Global Fertility Academy consists of two main parts: a theoretical e-learning part, and a practical training part. The newly launched website www.GlobalFertilityAcademy.org provides an online learning platform offering eight modules that cover topics ranging from the diagnosis of infertility to the business management of fertility clinics. Each module was designed by an internationally recognized fertility expert. After the participants have passed a mandatory e-learning module test, they can register for one of five different practice sessions. These individualized on-site trainings are proposed by over 20 selected leading in vitro fertilization (IVF) centers in Europe, North and Latin America, Asia and Australia and last for one week.
“The goal of the Global Fertility Academy is to share the experience of practicing fertility specialists to train physicians, researchers and fertility center staff in the theory, application and implementation of state-of-the art methods in the treatment of infertility,” said Dr. Antonio Pellicer, Professor of Obstetrics and Gynaecology at the University of Valencia, Spain, and one of the Academy’s faculty members. “This will be a valuable tool to provide the next generation of fertility professionals with the skills and excellence required to meet the needs of our patients.”
“The launch of the Global Fertility Academy, a unique program for medical education and sharing excellence, demonstrates that Merck Serono is committed to remain the leader in the fertility field,” said Dr. Frank Weber, Merck Serono’s Chief Medical Officer. “By offering services beyond our well-established pharmaceutical products for the treatment of infertility, we want to improve the success rate of current treatment methods, hoping to increase the number of babies born.”
The e-learning modules of the Global Fertility Academy have been submitted for continuing medical education (CME) accreditation with the European Accreditation Council for Continuing Medical Education (EACCME). The first module, entitled “Female Infertility Diagnosis and Management” (expert: Prof. A. Pellicer, Valencia, Spain) is already available; all further modules will be online by the end of the first quarter 2010. More information on scope and content of the Global Fertility Academy as well as on registration requirements and fees can be found on www.GlobalFertilityAcademy.org.
About Merck Serono and Fertility
Merck Serono is the world leader in fertility treatments. The company’s vision is to develop and provide innovative, easy-to-use products and devices, as well as patient care support services, to help infertile couples at every stage of the reproductive cycle: from follicular development to early pregnancy.
A pioneer in fertility treatments, Merck Serono is the only company to offer a full portfolio of fertility drugs for every stage of the reproductive cycle and recombinant versions of the three hormones needed to treat infertility: GONAL-f(R) FbM (follitropin alfa) to stimulate the ovaries and produce eggs; Luveris(R) (lutropin alfa), to stimulate follicular development in women who are profoundly LH deficient; PergoverisTM (follitropin alfa/lutropin alfa) to stimulate follicular development in women with severe LH and FSH deficiency; Cetrotide(R) (cetrorelix acetate) to prevent a premature ovulation; Ovitrelle(R) (choriogonadotropin alfa), to help follicles mature and release eggs; and Crinone(R) (progesterone gel), to help establish and maintain a pregnancy. With a portfolio of highly effective drugs, Merck Serono offers physicians the ability to tailor treatments to individual patients.
About Merck Serono
Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets innovative small molecules and biopharmaceuticals to help patients with unmet medical needs. Its North American business operates in the United States and Canada as EMD Serono.
Merck Serono has leading brands serving patients with cancer (Erbitux(R), cetuximab), multiple sclerosis (Rebif(R), interferon beta-1a), infertility (Gonal-f(R), follitropin alpha), endocrine and metabolic disorders (Saizen(R) and Serostim(R), somatropin), (Kuvan(R), sapropterin dihydrochloride) as well as cardiometabolic diseases (Glucophage(R), metformin), (Concor(R), bisoprolol), (Euthyrox(R), levothyroxine). Not all products are available in all markets.
With an annual R&D expenditure of around EUR 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in autoimmune and inflammatory diseases.
About Merck
Merck is a global pharmaceutical and chemical company with total revenues of EUR 7.6 billion in 2008, a history that began in 1668, and a future shaped by 32,700 employees in 60 countries. Its success is characterized by innovations from entrepreneurial employees. Merck’s operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
For more information, please visit www.merckserono.com or www.merck.de
(1) The Global Fertility Academy is supported by Merck Serono, and provided by Juwi MacMillan Group GmbH, an internationally operating healthcare agency specializing in medical education and communication technologies.
Source: Merck Serono
Media Relations : Merck Serono, Tel.: +41-22-414-36-00, 9 Chemin des Mines, 1202 Geneva, Switzerland.
Filed under Business, Education, Government and Policy, Health, Health Care / Hospitals, Multicultural, New Products / Services, Pharmaceuticals, Women Related | Tags: Europe, Geneva, Merck Serono, Switzerland | Comment Below
Related Press Releases Merck Serono Submits Application for Cladribine Tablets as a Potential Oral Short-Course Multiple Sclerosis Therapy in the United StatesSeptember 29th, 2009 GENEVA - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, Merck Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS). Cladribine Tablets has the potential to be the first orally administered disease-modifying therapy available for people living with relapsing MS, as all disease-modifying therapies currently approved for the treatment of MS are parenteral therapies. /C O R R E C T I O N -- Merck Serono S A/September 15th, 2009 GENEVA - In the news release, "Merck Serono Growth Hormone Injection Device easypod(R) Approved in Japan" issued on 16 Sep 2009 07:00 GMT, by Merck Serono S A SWX:SEO over PR Newswire, we are advised by a representative of the company that the last sentence of the fourth paragraph has been changed from "In Japan, easypod(R) will be launched in September 2009" to "In Japan, easypod(R) will be launched in the course of 2009" as originally issued inadvertently. Complete, corrected release follows:
Merck Serono, a division of Merck KGaA Darmstadt, Germany, today announced that the Japanese health authorities, the Pharmaceutical and Medical Devices Agency (PMDA), have granted a marketing authorization for easypod(R) in Japan. Merck Serono Growth Hormone Injection Device easypod(R) Approved in JapanSeptember 15th, 2009 GENEVA - Merck Serono, a division of Merck KGaA Darmstadt, Germany, today announced that the Japanese health authorities, the Pharmaceutical and Medical Devices Agency (PMDA), have granted a marketing authorization for easypod(R) in Japan. Easypod(R) was developed for exclusive use with cartridges of Saizen(R) (somatropin), Merck Serono's human recombinant growth hormone for the treatment of growth hormone deficiency. Merck Serono Submits Application for Cladribine Tablets as Multiple Sclerosis Therapy in EuropeJuly 22nd, 2009 GENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today the submission of a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for Cladribine Tablets, Merck Serono's proprietary investigational oral formulation of cladribine, as a therapy for patients with relapsing-remitting multiple sclerosis (MS). Cladribine Tablets could become the first orally administered disease-modifying therapy available for patients with MS, as all disease-modifying therapies currently approved for the treatment of MS are injectable. GONAL-f Approved in Japan for Ovulation Induction in Infertile WomenJuly 15th, 2009 GENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that the Japanese Ministry of Health, Labor and Welfare has granted approval to extend the indication of GONAL-f(R) (follitropin alfa for injection) to infertile women suffering from irregular or no ovulation (oligoovulation or anovulation) due to a dysfunction in the hypothalamic- pituitary system or polycystic ovarian syndrome. GONAL-f is a recombinant follicle-stimulating hormone currently approved in Japan for the treatment of male infertility. Merck Serono Committed to Investing in Innovation in the Fertility AreaMay 17th, 2009 GENEVA, Switzerland - Merck Serono, a division of Merck KGaA, Darmstadt, Germany, confirms its commitment to investing in the therapeutic area of fertility, after Merck KGaA informed earlier today the Oslo Stock Exchange of its withdrawal of the voluntary cash tender offer for MediCult A/S, a leader in Assisted Reproductive Technologies (ART), as the required share threshold was not reached in the set timeframe. "Merck Serono has a proud heritage of leadership in the field of fertility and will actively pursue opportunities that will contribute to bring further innovation to physicians and patients, and increase the success rate of fertility treatments," said Dr. Merck Serono Launches Glucophage(R) Powder (Metformin Hydrochloride) in First European CountriesMay 4th, 2009 FELTHAM, England - Innovative Powder Formulation of Metformin Designed to Facilitate Adherence by Increasing Patient Choice in the Treatment of Type 2 Diabetes, Now Available in France and the United Kingdom
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Glucophage(R) Powder for Oral Solution in Sachets, (metformin hydrochloride in 500mg, 850mg and 1000mg strengths) indicated for the first-line treatment of type 2 diabetes mellitus, is now licensed in France and the United Kingdom(1), the first European countries to launch this new formulation of Glucophage(R). Launches in other European countries are expected to take place in the coming months, once individual marketing authorisations are granted. Merck Serono Launches Glucophage Powder in First European CountriesMay 4th, 2009 GENEVA - Innovative Powder Formulation of Metformin Designed to Facilitate Adherence by Increasing Patient Choice in the Treatment of Type 2 Diabetes, Now Available in France and the United Kingdom
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Glucophage(R) Powder for Oral Solution in Sachets, (metformin hydrochloride in 500mg, 850mg and 1000mg strengths) indicated for the first-line treatment of type 2 diabetes mellitus, is now licensed in France and the United Kingdom(1), the first European countries to launch this new formulation of Glucophage. Launches in other European countries are expected to take place in the coming months, once individual marketing authorizations are granted. Merck Serono: New Phase III Data for Cladribine Tablets to be Presented at the American Academy of Neurology 61st Annual Meeting in April 2009March 29th, 2009 GENEVA, Switzerland - CLARITY (CLAdRIbine tablets Treating MS OrallY) Study Data to be
Presented as Late-Breaking Oral Presentation
GENEVA, Switzerland, March 30 /PRNewswire/ --
Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
announced today that the American Academy of Neurology (AAN) has accepted a
late-breaking abstract regarding cladribine tablets, its oral investigational
treatment of multiple sclerosis, for an oral presentation at the AAN 61st
Annual Meeting in Seattle. The abstract is entitled "Results from the CLARITY study: a
Phase III, randomized, double-blind study to evaluate the safety and efficacy
of oral cladribine in relapsing-remitting multiple sclerosis". Merck Serono Launches Strategic Venture Capital FundMarch 22nd, 2009 GENEVA, Switzerland - New Venture Capital Fund Will Invest in Biotech Start-up Companies
Focused on Merck Serono's Core Therapeutic Areas
Merck Serono, a division of Merck KGaA, Darmstadt, Germany,
announced today the formation of 'Merck Serono Ventures', a strategic,
corporate venture capital fund to invest in emerging biotechnology companies. The fund will support biotech start-up companies that have the potential to
provide innovative products in Merck Serono's core therapeutic areas, in
particular in Neurodegenerative Diseases, Oncology and Autoimmune &
Inflammatory Diseases.
Related News 'KISS' therapy offers new hope for infertile womenMarch 17th, 2009 WASHINGTON - British researchers claim that hormone kisspeptin shows promise as a potential new treatment for infertility. The study, led by Dr Waljit Dhillo from Imperial College London, has shown that giving kisspeptin to women with infertility can activate the release of sex hormones, which control the menstrual cycle. IVF baby girl born from 21-year old frozen spermApril 13th, 2009 WASHINGTON - Fertility specialists heralded the birth of a baby girl who was conceived through in-vitro fertilisation (IVF) at their lab with sperm frozen 21 years ago, a world record. Chris Biblis, 38, of Charlotte (US) was treated for leukemia from age 13 to 18. Kisspeptin stimulates sex hormone in infertile womenMarch 17th, 2009 LONDON - Hormone kisspeptin shows promise as a potential new treatment for infertility in women, according to a new study. Scientists of Imperial College have shown that giving kisspeptin to women with infertility can activate the release of sex hormones which control the menstrual cycle. Stress delivers double whammy to reproductive system, fertilityJune 16th, 2009 WASHINGTON - Researchers from University of California, Berkeley claim to have found a missing piece of puzzle about how stress causes sexual dysfunction and infertility. The study showed that stress delivers a double whammy on reproductive system and fertility. German drug, chemical maker Merck second quarter net profit falls 48 percent to euro109 millionJuly 24th, 2009 Merck Q2 net profit falls 48 percent to euro109 MFRANKFURT — German drug and chemical maker Merck KGaA said Friday its second quarter net profit fell 48 percent as higher research costs and one-time effects from the acquisition of Serono weighed on the bottom line. The Darmstadt-based company reported a net profit of euro108 million ($153 million) in the April-June period compared with euro207 million a year earlier. When should women be ready for a baby?January 10th, 2009 WASHINGTON - Young women might not like to have a baby now, but will they be able to have one by the time they decide?
For women in 20s, preventing infertility is ignored until it's too late. Most young women are advised to do everything possible to keep pregnancy at bay, without thinking about its long term consequences. Toonz Academy ties up with Anna UniversityJuly 9th, 2009 THIRUVANANTHAPURAM - Toonz Academy, a leading animation training institute, has tied up with the Anna University Coimbatore, it was announced Thursday. Toonz Academy is the training division of the Toonz Animation Studios operating from the Technopark campus here. Firing reported near police training academy in LahoreApril 10th, 2009 ISLAMABAD - A blast occurred near a police training academy in Pakistan's Lahore city Friday followed by an exchange of fire, media reported. Gunshots were being heard from a distance of half a kilometre from the police training academy, Geo TV channel quoted an eye-witness as saying. IVF success lower in women who used alternative fertility treatmentAugust 19th, 2009 WASHINGTON - A new study from Denmark has revealed that the success of in vitro fertilization (IVF) treatment is 30 percent lower among women who have used alternative fertility medicine. For the study, the researchers included over 700 IVF users over a 12-month period. Kashmiri girls all set to be airhostessesMay 10th, 2009 SRINAGAR - Many Kashmiri girls have opted to explore career options in aviation industry by undertaking courses in aviation sector to be airhostesses and enjoy travelling across the world. Several young girls and also boys are now joining courses to get training for flight attendants and other related jobs in the aviation sector to fulfill their dreams.
|
|
